Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Statins enhance efficacy of venetoclax in blood cancers.

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaaq1240. doi: 10.1126/scitranslmed.aaq1240.

PMID:
29899021
2.

Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.

Thompson JM, Alvarez A, Singha MK, Pavesic MW, Nguyen QH, Nelson LJ, Fruman DA, Razorenova OV.

Mol Cancer Ther. 2018 Aug;17(8):1781-1792. doi: 10.1158/1535-7163.MCT-17-1076. Epub 2018 May 2.

PMID:
29720560
3.

The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells.

Karimzadeh A, Scarfone VM, Varady E, Chao C, Grathwohl K, Fathman JW, Fruman DA, Serwold T, Inlay MA.

Stem Cells Transl Med. 2018 Jun;7(6):468-476. doi: 10.1002/sctm.17-0189. Epub 2018 Mar 15.

4.

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.

Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M.

Oncotarget. 2018 Jan 17;9(8):8027-8041. doi: 10.18632/oncotarget.24261. eCollection 2018 Jan 30.

5.

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

Gotesman M, Vo TT, Herzog LO, Tea T, Mallya S, Tasian SK, Konopleva M, Fruman DA.

Oncotarget. 2018 Jan 6;9(5):6562-6571. doi: 10.18632/oncotarget.24020. eCollection 2018 Jan 19.

6.

The PI3K Pathway in Human Disease.

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT.

Cell. 2017 Aug 10;170(4):605-635. doi: 10.1016/j.cell.2017.07.029. Review.

7.

The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.

Chiu H, Mallya S, Nguyen P, Mai A, Jackson LV, Winkler DG, DiNitto JP, Brophy EE, McGovern K, Kutok JL, Fruman DA.

Front Immunol. 2017 Jun 30;8:747. doi: 10.3389/fimmu.2017.00747. eCollection 2017.

8.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2017 Jun 1;127(6):2438. doi: 10.1172/JCI95182. Epub 2017 Jun 1. No abstract available.

9.

mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.

Vo TT, Lee JS, Nguyen D, Lui B, Pandori W, Khaw A, Mallya S, Lu M, Müschen M, Konopleva M, Fruman DA.

Mol Cancer Ther. 2017 Sep;16(9):1942-1953. doi: 10.1158/1535-7163.MCT-17-0024. Epub 2017 May 31.

10.

Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling.

Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR.

J Biol Chem. 2017 Mar 31;292(13):5608. doi: 10.1074/jbc.A117.305602. No abstract available.

11.

Cancer: A targeted treatment with off-target risks.

Fruman DA, O'Brien S.

Nature. 2017 Feb 23;542(7642):424-425. doi: 10.1038/nature21504. Epub 2017 Feb 15. No abstract available.

12.

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA, Honig B, Landry DW, O'Connor OA.

Blood. 2017 Jan 5;129(1):88-99. doi: 10.1182/blood-2016-08-731240. Epub 2016 Oct 26.

13.

Context-Specific Function of S6K2 in Th Cell Differentiation.

Pai C, Walsh CM, Fruman DA.

J Immunol. 2016 Oct 15;197(8):3049-3058. Epub 2016 Sep 9.

14.

Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing.

Hong CA, Cho SK, Edson JA, Kim J, Ingato D, Pham B, Chuang A, Fruman DA, Kwon YJ.

ACS Nano. 2016 Sep 27;10(9):8705-14. doi: 10.1021/acsnano.6b04155. Epub 2016 Aug 5.

15.

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.

Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M.

Oncotarget. 2016 Aug 23;7(34):55083-55097. doi: 10.18632/oncotarget.10397.

16.

mTOR signaling: new networks for ALL.

Fruman DA.

Blood. 2016 Jun 2;127(22):2658-9. doi: 10.1182/blood-2016-03-703199. No abstract available.

17.

The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes.

So L, Lee J, Palafox M, Mallya S, Woxland CG, Arguello M, Truitt ML, Sonenberg N, Ruggero D, Fruman DA.

Sci Signal. 2016 May 31;9(430):ra57. doi: 10.1126/scisignal.aad8463.

18.

Targeting mTOR for the treatment of B cell malignancies.

Lee JS, Vo TT, Fruman DA.

Br J Clin Pharmacol. 2016 Nov;82(5):1213-1228. doi: 10.1111/bcp.12888. Epub 2016 Mar 3. Review.

19.

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.

Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA.

Oncotarget. 2015 Nov 3;6(34):35202-17. doi: 10.18632/oncotarget.6051.

20.

INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency.

Vo TT, Fruman DA.

Cancer Discov. 2015 Jul;5(7):697-700. doi: 10.1158/2159-8290.CD-15-0609.

Supplemental Content

Loading ...
Support Center